Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OptimizeRx CorpOPRX · Entity 213 | Director | June 09, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OptimizeRx Corp
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 78,732 |
Reported balance
After 2026-06-09 transaction · row 1
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 34,517 · Balance 78,732 F1: Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in full on the earlier of the first anniversary of the date of the grant or the date of the Company's next annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in full on the earlier of the first anniversary of the date of the grant or the date of the Company's next annual meeting of shareholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 10, 2026 17:38 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 34,517 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-042130 · wk-form4_1781113100.xml · nonDerivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,732 F1 · shares: Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in full on the earlier of the first anniversary of the date of the grant or the date of the Company's next annual meeting of shareholders. Read SEC document |
| August 28, 2025 Filed Sep 11, 2025 17:55 UTC | OptimizeRx Corp OPRX · Entity 213 | SaleCommon Stock | 11,120 | $17.49 | $194,488.80 |
DisclosureSEC source: 0001296525-25-000002 · wk-form4_1757613304.xml · nonDerivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,215 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.47 through $18.43. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, complete information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 20:34 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 9,868 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-031021 · wk-form4_1749760489.xml · nonDerivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,335 F1 · shares: Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in full on the earlier of the first anniversary of the date of the grant or the date of the Company's next annual meeting of shareholders. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 21:50 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 13,286 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-027716 · wk-form4_1718142621.xml · nonDerivative · entry 2 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,467 F2 · shares: Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's next annual meeting of shareholders. Read SEC document |
| June 05, 2024 Filed Jun 11, 2024 21:50 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionRestricted Stock Units · Derivative | 10,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-027716 · wk-form4_1718142621.xml · derivative · entry 3 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,061 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On June 7, 2023 the reporting person was granted 10,061 restricted stock units which vested in full on June 5, 2024. F3 · derivative.expiration_date: On June 7, 2023 the reporting person was granted 10,061 restricted stock units which vested in full on June 5, 2024. Read SEC document |
| June 05, 2024 Filed Jun 11, 2024 21:50 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 10,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-027716 · wk-form4_1718142621.xml · nonDerivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 07, 2023 Filed Aug 18, 2023 13:33 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantRestricted Stock Units · Derivative | 10,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-029930 · wk-form4_1692365605.xml · derivative · entry 3 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,061 Underlying: Common Stock · 10,061 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. F4 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's next annual meeting of shareholders. F4 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's next annual meeting of shareholders. Read SEC document |
| June 07, 2023 Filed Aug 18, 2023 13:33 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionRestricted Stock Units · Derivative | 4,637 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-029930 · wk-form4_1692365605.xml · derivative · entry 2 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,637 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On June 7, 2022 the reporting person was granted 4,637 restricted stock units which vested in full on June 7, 2023. F2 · derivative.expiration_date: On June 7, 2022 the reporting person was granted 4,637 restricted stock units which vested in full on June 7, 2023. Read SEC document |
| June 07, 2023 Filed Aug 18, 2023 13:33 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 4,637 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-029930 · wk-form4_1692365605.xml · nonDerivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 16:19 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionRestricted Stock Units · Derivative | 657 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-010320 · wf-form4_168053877805362.xml · derivative · entry 2 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 657 Underlying: Common Stock · 657 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On March 30, 2022 the reporting person was granted 657 restricted stock units which vested in full on March 30, 2023. F2 · derivative.expiration_date: On March 30, 2022 the reporting person was granted 657 restricted stock units which vested in full on March 30, 2023. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 16:19 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 657 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-010320 · wf-form4_168053877805362.xml · nonDerivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:04 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionRestricted Stock Units · Derivative | 409 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-000211 · wf-form4_167286627832143.xml · derivative · entry 2 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 409 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On December 30, 2021 the reporting person was granted 409 restricted stock units which vested in full on December 30, 2022. F2 · derivative.expiration_date: On December 30, 2021 the reporting person was granted 409 restricted stock units which vested in full on December 30, 2022. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:04 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 409 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-000211 · wf-form4_167286627832143.xml · nonDerivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| September 29, 2022 Filed Sep 30, 2022 20:48 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionRestricted Stock Units · Derivative | 334 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-025812 · wf-form4_166457091189748.xml · derivative · entry 2 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On September 29, 2021 the reporting person was granted 334 restricted stock units which vested in full on September 29, 2022. F2 · derivative.expiration_date: On September 29, 2021 the reporting person was granted 334 restricted stock units which vested in full on September 29, 2022. Read SEC document |
| September 29, 2022 Filed Sep 30, 2022 20:48 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 334 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-025812 · wf-form4_166457091189748.xml · nonDerivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:45 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantRestricted Stock Units · Derivative | 4,637 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-032531 · ownership.xml · derivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,637 Underlying: Common Stock · 4,637 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. F2 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's next annual meeting of shareholders. F2 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's next annual meeting of shareholders. Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 20:48 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantRestricted Stock Units · Derivative | 657 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-017502 · ownership.xml · derivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 657 Underlying: Common Stock · 657 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. F2 · derivative.exercise_date: The restricted stock units vest on March 30, 2023. F2 · derivative.expiration_date: The restricted stock units vest on March 30, 2023. Read SEC document |
| December 30, 2021 Filed Jan 3, 2022 21:45 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantRestricted Stock Units · Derivative | 409 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-000275 · ownership.xml · derivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 743 Underlying: Common Stock · 409 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: Grant to the Reporting Person of restricted stock units under the OptimizeRx Corp. 2021 Equity Incentive Plan. The restricted stock units granted vest on December 30, 2022, subject to continued service to the issuer through the vesting date. This restricted stock units granted are subject to accelerated vesting in the event that the recipient is subject to a qualified termination within a specified period of time prior to or following the closing of a change in control transaction. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 21:45 UTC | OptimizeRx Corp OPRX · Entity 213 | SaleCommon Stock (pursuant to 10B5-1 plan) | 6,252 | $84.38 | $527,543.76 |
DisclosureSEC source: 0001213900-21-059450 · ownership.xml · nonDerivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,083 F1 · security: These shares sold pursuant to a plan of disposition adopted on September 7, 2021 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 29, 2021 Filed Oct 1, 2021 20:45 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantRestricted Stock Units · Derivative | 334 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-051138 · ownership.xml · derivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334 Underlying: Common Stock · 334 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: Grant to the Reporting Person of restricted stock units under the OptimizeRx Corp. 2021 Equity Incentive Plan. The restricted stock units granted vest on September 29, 2022, subject to continued service to the issuer through the vesting date. This restricted stock units granted are subject to accelerated vesting in the event that the recipient is subject to a qualified termination within a specified period of time prior to or following the closing of a change in control transaction. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| June 30, 2021 Filed Jun 30, 2021 20:48 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 407 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-035080 · ownership.xml · nonDerivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,335 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 16:40 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 539 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-019880 · ownership.xml · nonDerivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,928 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 21:45 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 802 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-000456 · ownership.xml · nonDerivative · entry 2 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,389 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| September 30, 2020 Filed Jan 5, 2021 21:45 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 1,183 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-000456 · ownership.xml · nonDerivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,587 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:35 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 1,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-016584 · ownership.xml · nonDerivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,404 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| March 30, 2020 Filed Mar 31, 2020 12:47 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 2,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-008140 · ownership.xml · nonDerivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,467 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 21:31 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 2,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-000384 · ownership.xml · nonDerivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,683 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 21:17 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 2,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-019543 · ownership.xml · nonDerivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,599 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| March 29, 2019 Filed Mar 29, 2019 20:21 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 2,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-005245 · ownership.xml · nonDerivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,347 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| October 08, 2018 Filed Oct 10, 2018 21:20 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 2,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-18-013768 · ownership.xml · nonDerivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,263 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 18:43 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 2,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-18-008680 · ownership.xml · nonDerivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,179 F1 · price: The Issuer issued these shares to the Reporting Person under the Director Compensation Plan. Read SEC document |
| June 27, 2018 Filed Jun 28, 2018 16:55 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 95 | $9.95 | $945.25 |
DisclosureSEC source: 0001213900-18-008414 · ownership.xml · nonDerivative · entry 1 Spangler Patrick D · CIK 0001296525 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.